Cypherpunk Technologies (NASDAQ:CYPH) Given New $1.60 Price Target at Cantor Fitzgerald

Key Points

• Cantor Fitzgerald raised Cypherpunk Technologies’ price target to $1.60 from $0.90 and maintained an “overweight” rating, implying approximately 98.66% upside from the stock’s $0.81 price.
• Analyst sentiment remains mixed: one analyst rates the stock Buy and another Sell, resulting in a consensus “Hold” rating and a $1.60 average price target.
• Institutional investors own 30.46% of the company, while Cypherpunk reported quarterly EPS of $0.18 and continues developing cancer therapies alongside a Zcash-focused digital asset treasury strategy.

Cypherpunk Technologies (NASDAQ:CYPH - Get Free Report) had its target price raised by analysts at Cantor Fitzgerald from $0.90 to $1.60 in a report released on Wednesday,Benzinga reports. The firm currently has an "overweight" rating on the stock. Cantor Fitzgerald's price target indicates a potential upside of 98.66% from the company's current price.

CYPH has been the subject of several other research reports. Wall Street Zen upgraded shares of Cypherpunk Technologies from a "sell" rating to a "hold" rating in a research report on Saturday, July 4th. Weiss Ratings raised Cypherpunk Technologies from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Monday. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Cypherpunk Technologies has an average rating of "Hold" and a consensus price target of $1.60.

Cypherpunk Technologies Price Performance

CYPH stock opened at $0.81 on Wednesday. The firm has a market cap of $86.79 million, a PE ratio of 1.44 and a beta of 0.09. Cypherpunk Technologies has a 12 month low of $0.26 and a 12 month high of $3.70. The firm has a 50 day simple moving average of $0.68 and a 200 day simple moving average of $0.78.

Cypherpunk Technologies (NASDAQ:CYPH - Get Free Report) last posted its quarterly earnings results on Wednesday, August 12th. The company reported $0.18 earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On Cypherpunk Technologies

A number of hedge funds have recently bought and sold shares of CYPH. Simplify Asset Management Inc. bought a new stake in shares of Cypherpunk Technologies in the fourth quarter valued at about $2,172,000. Acadian Asset Management LLC grew its holdings in shares of Cypherpunk Technologies by 470.4% during the 1st quarter. Acadian Asset Management LLC now owns 1,280,531 shares of the company's stock worth $389,000 after purchasing an additional 1,056,047 shares in the last quarter. Renaissance Technologies LLC bought a new stake in shares of Cypherpunk Technologies during the first quarter valued at approximately $576,000. Geode Capital Management LLC acquired a new position in shares of Cypherpunk Technologies in the fourth quarter valued at $615,000. Finally, State Street Corp acquired a new position in shares of Cypherpunk Technologies in the fourth quarter valued at $163,000. 30.46% of the stock is currently owned by institutional investors.

About Cypherpunk Technologies

Cypherpunk Technologies Inc, previously known as Leap Therapeutics, Inc, is a company developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash. The company’s research platform centers on modulating the tumor microenvironment to enhance anti-tumor immune responses. Cypherpunk’s proprietary pipeline includes DKN-01, a monoclonal antibody designed to neutralize Dickkopf-1 (DKK1), a protein implicated in tumor growth and immune evasion.

DKN-01 is being evaluated both as a monotherapy and in combination with checkpoint inhibitors such as pembrolizumab across multiple solid tumor indications, including gastroesophageal, pancreatic and other advanced malignancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source